Updated CAPItello-281 analysis shows OS benefit with capivasertib-abiraterone in PTEN-deficient mHSPC

Retrospective · Ann Oncol · 2026-10-24. Number 3 in the UrologyWatch Top 5 for October 24, 2026.

In an ad hoc, non-prespecified descriptive analysis of the phase 3 CAPItello-281 trial at 42% survival data maturity (median follow-up 39 months), capivasertib plus abiraterone showed an overall survival benefit over placebo plus abiraterone in PTEN-deficient de novo mHSPC (median 57.4 vs 46.5 months, HR 0.82, 95% CI 0.68-0.99, P=0.044), consistent with the updated radiographic progression-free survival benefit (HR…

Why it matters: A descriptive, non-prespecified interim update suggests a survival benefit in PTEN-deficient mHSPC; results are from an ad hoc analysis, not a prespecified final analysis.

Limitation: Analysis was descriptive and not prespecified in the protocol; survival data still immature (42%).

Source: Ann Oncol · PubMed 42918424 · DOI 10.1016/j.annonc.2026.10.097

The full October 24, 2026 edition · Today's urology news